METABOLIC / SINGLE
TIRZEPATIDE
5MG · 10MG · 15MG · 20MG · 30MG · 40MG · 50MG · 60MG · 100MG · 120MGThis content is intended for educational and research reference only and does not constitute medical advice, diagnosis, or treatment. Experimental compounds are for research use only and are not for human consumption. Always consult qualified healthcare providers before starting any therapy.
Research Overview
A dual GLP-1/GIP receptor agonist studied in glucose regulation and weight-management research.
Available Strengths
- 5MG (TR5)
- 10MG (TR10)
- 15MG (TR15)
- 20MG (TR20)
- 30MG (TR30)
- 40MG (TR40)
- 50MG (TR50)
- 60MG (TR60)
- 100MG (TR100)
- 120MG (TR120)
Research Protocol
Reference gradual titration
| Period | Dose | U-100 units | Volume |
|---|---|---|---|
| Weeks 1–4 | 2.5 mg | 100 | 1 mL |
| Weeks 5–8 | 5 mg | 200 | 2 mL |
| Weeks 9–12 | 7.5 mg | 300 | 3 mL |
| Weeks 13–16 | 10 mg | 400 | 4 mL |
Reconstitution
≈2.5 mg/mL once reconstituted
- Draw 2.0 mL of bacteriostatic water per 5 mg vial.
- Inject slowly along the vial wall to avoid foaming; swirl gently until dissolved.
Research context
Dual receptor agonism is studied for enhancing glucose-dependent insulin secretion, suppressing glucagon and slowing gastric emptying; an approximately five-day half-life supports once-weekly dosing in the reference protocol.
Storage
−20°C, dry conditions. 2–8°C, do not freeze; use within 28 days.
Research Notes
- For educational and research reference only. Not medical advice and not intended for unsupervised human use.
- Approved tirzepatide medicines use fixed proprietary formulations; this research vial is not interchangeable with them.
References
Source reference: PeptideDosages.com · 2026-08-18 · Exact strength match with the cited source